{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T21:47:29Z","timestamp":1726436849009},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Programa\u2010I3SNS"],"award-info":[{"award-number":["Programa\u2010I3SNS"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to analyse the frequency and degree of potential drug\u2212drug interactions (<jats:styled-content style=\"fixed-case\">DDI<\/jats:styled-content>s) between direct\u2010acting antivirals (<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s) and concomitant medication used by <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\/hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>)\u2010coinfected patients, including antiretroviral therapy (<jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>) and other drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> infection and viraemic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1, 3 or 4 coinfection attending a tertiary care centre in Spain (November 2014 to November 2015) were included in the study. <jats:styled-content style=\"fixed-case\">DDI<\/jats:styled-content>s were classified as major, i.e. drugs should not be co\u2010administered, or minor, i.e. close monitoring, dosage alteration or change in timing may be required if drugs are co\u2010administered, following the <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.hep-druginteractions.org\">http:\/\/www.hep-druginteractions.org<\/jats:ext-link> database recommendations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 244 patients were included in the study, of whom 224 (92%) were previous injecting drug users. Major <jats:styled-content style=\"fixed-case\">DDI<\/jats:styled-content>s were found for: paritaprevir\u2010r\/ombitasvir plus dasabuvir (3D), in 60 (44%) of 138 individuals with genotype 1; paritaprevir\u2010r\/ombitasvir (2D), in 22 (37%) of 60 individuals with genotype 4; sofosbuvir\/ledipasvir (<jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content>), in four (2%) of 198 patients with genotype 1 or 4; simeprevir (<jats:styled-content style=\"fixed-case\">SMV<\/jats:styled-content>) plus <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>, in 160 (81%) of 198 patients with genotype 1 or 4; daclatasvir (<jats:styled-content style=\"fixed-case\">DCV<\/jats:styled-content>) plus <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>, in seven (3%) of 244 patients with genotype 1, 3 or 4 (<jats:italic>P<\/jats:italic> &lt; 0.001). Minor <jats:styled-content style=\"fixed-case\">DDI<\/jats:styled-content>s were found for: 3D, in 123 (89%) individuals with genotype 1; 2D, in 52 (87%) individuals with genotype 4; <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content>, in 154 (78%) patients with genotype 1 or 4; <jats:styled-content style=\"fixed-case\">SMV<\/jats:styled-content> plus <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>, in 129 (65%) patients with genotype 1 or 4; <jats:styled-content style=\"fixed-case\">DCV<\/jats:styled-content> plus <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>, in 149 (61%) patients with genotype 1, 3 or 4 (<jats:italic>P<\/jats:italic> &lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Drug\u2212drug interactions between <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s and <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> or other commonly prescribed medications are frequently found among <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010coinfected patients. Potential major and minor <jats:styled-content style=\"fixed-case\">DDI<\/jats:styled-content>s are more frequent with 3D, 2D and <jats:styled-content style=\"fixed-case\">SMV<\/jats:styled-content> plus <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content> regimens.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12471","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T09:52:41Z","timestamp":1479981161000},"page":"445-451","source":"Crossref","is-referenced-by-count":12,"title":["High frequency of potential interactions between direct\u2010acting antivirals and concomitant therapy in <scp>HIV<\/scp>\/hepatitis C virus\u2010coinfected patients in clinical practice"],"prefix":"10.1111","volume":"18","author":[{"given":"J","family":"Mac\u00edas","sequence":"first","affiliation":[{"name":"Infectious Diseases and Microbiology Unit Hospital Universitario de Valme Seville Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS) Seville Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Monge","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit Hospital Universitario de Valme Seville Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mancebo","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit Hospital Universitario de Valme Seville Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Merchante","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit Hospital Universitario de Valme Seville Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS) Seville Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Neukam","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit Hospital Universitario de Valme Seville Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS) Seville Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LM","family":"Real","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit Hospital Universitario de Valme Seville Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS) Seville Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JA","family":"Pineda","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit Hospital Universitario de Valme Seville Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1328"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503153"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0036390"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040842"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1433-5"},{"key":"e_1_2_6_12_1","unstructured":"NeukamK Rivero\u2010Ju\u00e1rezA Morano\u2010AmadoLEet al.Impact of HIV coinfection on the efficacy and safety of direct\u2010acting antiviral\u2010based therapy against chronic hepatitis C under real\u2010life conditions: Combined results from the HEPAVIR\u2010DAA and the GEHEP\u2010MONO (GEHEP\u2010001) cohorts.I Congreso Nacional del Grupo de Estudio de las Hepatitis V\u00edricas de la SEIMC. Vigo Spain. September 24\u201326 20152015 OR\u201004."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506816"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62041-9"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70796-0"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70782-0"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141164"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2014.0215"},{"key":"e_1_2_6_19_1","unstructured":"LangnessJ LarsonB BayerJ RoyersM KiserJ.Readying HIV\/HCV coinfected patients for HCV treatment: occurrence and management of antiviral interactions16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. May 26\u201328 2015. Washington DC USA2015."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79824-X"},{"key":"e_1_2_6_21_1","unstructured":"WylesD MangiaA ChengW et al.Long\u2010term persistence of HCV NS5S variants after treatment with NS5A inhibitor ledipasvir.50th Annual Meeting of the European Association for the Study of the Liver (EASL). April 22\u201326 2015; Vienna Austria.2015 RS\u20102225."},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","unstructured":"LawitzE FlammS YangJC et al.Retreatment of patients who failed 8 or 12 weeks of ledipasvir\/sofosbuvir\u2010based regimens with ledipasvir\/sofosbuvir for 24 weeks.50th Annual Meeting of the European Association for the Study of the Liver (EASL). April 22\u201326 2015; Vienna Austria.2015 RS\u20101627.","DOI":"10.1016\/S0168-8278(15)30012-X"},{"key":"e_1_2_6_23_1","unstructured":"TerraultN ZeuzemS Di BisceglieAMet al.Treatment outcomes with 8 12 and 24 week regimens of ledipasvir\/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective observational study.Program and abstracts of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases; November 13\u201317 2015; San Francisco California.2015 Abstract 94."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12471","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:12:22Z","timestamp":1695492742000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/hiv.12471"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12471","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2016,11,24]]}}}